ストックスクリーナーアプリを入手
10.28
11.61%
-1.35
アフターアワーズ：
10.24
-0.04
-0.39%
前日終値:
$11.63
開ける：
$11.77
24時間の取引高:
203.34K
Relative Volume:
1.57
時価総額：
$58.33M
収益：
$62.39M
当期純損益:
$-181.05M
株価収益率:
-3.4966
EPS:
-2.94
ネットキャッシュフロー:
$-142.49M
1週間 パフォーマンス:
+15.90%
1か月 パフォーマンス:
+33.68%
6か月 パフォーマンス:
-38.63%
1年 パフォーマンス:
-68.12%
1日の値動き範囲:
$9.945
$11.87
1週間の範囲:
$8.80
$11.87
52週間の値動き範囲:
$4.965
$39.50
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
名前
Atara Biotherapeutics Inc
セクター
電話
805-623-4244
住所
2380 CONEJO SPECTRUM ST, THOUSAND OAKS, CA
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-20 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-07-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-07-13 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-05-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 開始されました | Evercore ISI | Outperform |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-23 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-09-27 | ダウングレード | Goldman | Neutral → Sell |
| 2019-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2019-06-04 | アップグレード | Citigroup | Sell → Neutral |
| 2019-05-30 | 開始されました | ROTH Capital | Buy |
| 2019-05-23 | 開始されました | Stifel | Buy |
| 2019-01-23 | 開始されました | Mizuho | Buy |
| 2018-04-10 | 開始されました | JP Morgan | Overweight |
| 2018-03-16 | 開始されました | Guggenheim | Neutral |
| 2018-03-05 | 繰り返されました | Jefferies | Buy |
| 2018-02-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-01-03 | アップグレード | Citigroup | Sell → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Atara Biotherapeutics Inc (ATRA) 最新ニュース
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Business Wire
Vanguard Group Inc's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus.com
Hemophagocytic Lymphohistiocytosis Market to Reach New Heights in Growth by 2034, DelveInsight Predict | Incyte, Novartis, Atara Biotherapeutics, Bellicum Pharma - The Globe and Mail
(ATRA) Trading Signals - Stock Traders Daily
How the (ATRA) price action is used to our Advantage - Stock Traders Daily
Atara Biotherapeutics names new COO By Investing.com - Investing.com Australia
Atara Biotherapeutics names new COO - Investing.com
Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer - Marketscreener.com
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How to Take Advantage of moves in (ATRA) - Stock Traders Daily
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - Yahoo Finance
Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart
Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily
How To Trade (ATRA) - Stock Traders Daily
Atara Therapeutics appoints Cokey Nguyen as chief executive - The Pharma Letter
Atara Biotherapeutics Sees Its Stock Price Rise - Los Angeles Business Journal
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On? - MSN
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St
Atara Biotherapeutics Inc [ATRA] President and CEO makes an insider purchase of 3,038 shares worth 20139.0. - Knox Daily
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal
Atara Biotherapeutics secures $36 million in stock sale - Investing.com
Atara Biotherapeutics Shares Climb on $36 Million Direct Offering - MarketWatch
Atara Biotherapeutics Announces Board Appointment and Capital Raise - TipRanks
Atara Biotherapeutics Announces $36 Million Registered Direct Offering - StockTitan
Atara Biotherapeutics Inc’s latest rating changes from various analysts - Knox Daily
(ATRA) Proactive Strategies - Stock Traders Daily
Atara Biotherapeutics EVP sells over $7k in company stock - Investing.com India
Atara biotherapeutics EVP sells shares worth over $6,300 - Investing.com India
Atara Biotherapeutics EVP sells over $7k in company stock By Investing.com - Investing.com South Africa
Atara biotherapeutics EVP sells shares worth over $6,300 By Investing.com - Investing.com South Africa
Atara Biotherapeutics EVP sells shares worth over $7,600 - Investing.com India
Atara Biotherapeutics CEO sells over $20k in company stock - Investing.com
Atara biotherapeutics EVP sells shares worth over $12,000 - Investing.com
Atara Biotherapeutics EVP sells shares worth over $7,600 By Investing.com - Investing.com Canada
Atara biotherapeutics EVP sells shares worth over $12,000 By Investing.com - Investing.com UK
Alzamend Neuro (ALZN) Could Triple from current levels and here’w why - BP Journal
Mizuho Upgrades Atara Biotherapeutics (NASDAQ:ATRA) to Outperform - Defense World
Mizuho upgrades Atara Biotherapeutics, cuts stock target on positive outlook By Investing.com - Investing.com Canada
CRISPR-focused Caribou christens new CMO—Chutes & Ladders - Fierce Biotech
Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA - Longview News-Journal
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results - Defense World
Atara Biotherapeutics’ (ATRA) Buy Rating Reaffirmed at Canaccord Genuity Group - Defense World
Atara Biotherapeutics (NASDAQ:ATRA) Posts Earnings Results, Misses Estimates By $1.54 EPS - Defense World
Atara Biotherapeutics Second Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates - MSN
Atara Biotherapeutics: Q2 Earnings Snapshot - Darien Times
Atara Biotherapeutics Announces CEO Transition and New Leadership Compensation - TipRanks
Atara Biotherapeutics Inc (ATRA) 財務データ
収益
当期純利益
現金流量
EPS
Atara Biotherapeutics Inc (ATRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nguyen AnhCo | EVP, Chief Sci. & Tech Officer |
Aug 16 '24 |
Sale |
6.63 |
1,821 |
12,072 |
34,118 |
| Murugan Amar | EVP, Chief Legal Officer |
Aug 16 '24 |
Sale |
6.63 |
1,158 |
7,677 |
26,827 |
| Hyllengren Eric J | EVP, CFO |
Aug 16 '24 |
Sale |
6.63 |
1,070 |
7,093 |
24,756 |
| Henrich Jill | EVP, Global Head RA & Quality |
Aug 16 '24 |
Sale |
6.63 |
963 |
6,384 |
20,378 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):